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Recent advances in febrile neutropenia (FN) have highlighted the value of risk stratification and the evolving role of oral antibiotics
with early hospital discharge in low-risk patients. The aim of this study was to survey whether these advances have been translated
into routine clinical practice in the UK. Questionnaires were sent to cancer clinicians across the UK to determine clinicians’ routine
management of FN, including use of risk stratification, antibiotic regimen and criteria for hospital discharge. In all, 128 clinicians
responded, representing 50 cancer departments (83%). Only 38% of respondents stratify patients according to risk and with
substantial variation in the criteria defining ‘low-risk’. Furthermore, only 22% of clinicians use oral antibiotics as first-line treatment in
any patients with FN, but this was significantly greater among clinicians who do compared to those who do not stratify patients
by risk, 51 vs 4% (Po0.0001). These findings suggest a slow and/or cautious introduction of newer strategies for the management
of low-risk FN in the UK. However, 84% of respondents confirmed their willingness to participate in a trial of oral antibiotics
combined with early discharge in low-risk FN.
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For more than 30 years the standard management for all patients
developing febrile episodes while neutropenic has been in-patient
treatment with broad spectrum intravenous (i.v.) antibiotics
(Hughes et al, 1990; Bodey et al, 1997; Hughes et al, 1997).
However, recent evidence has prompted a re-assessment of febrile
neutropenia (FN), with increasing realisation that such intensive
treatment may not be necessary or appropriate for all patients.
This viewpoint has stemmed from the recognition that FN is not
a single entity but rather represents a spectrum of severity. Only
a small proportion of patients with FN will develop serious medical
complications (16% overall, 12% of patients with solid tumours/
lymphomas and 18% of patients with haematological malignan-
cies) and fewer than 5% will die as a result of the episode (4.8%;
Klastersky et al, 2000). Thus a majority of episodes of FN may be
described as being ‘low-risk’. Several groups of investigators have
independently developed prognostic indices in FN in an attempt to
identify criteria by which to define ‘low-risk’ (Rubin et al, 1988;
Talcott et al, 1992; Viscoli et al, 1994; Elting et al, 1997; Talcott
et al, 1998). More recently these groups have come together in an
international collaboration with the publication of the Multi-
national Association for Supportive Care in Cancer (MASCC) ‘risk
index’ (Klastersky et al, 2000). In this study more than 40 possible
risk factors for the development of significant medical complica-
tions at presentation of FN were examined in an initial derivation
set of 756 patients. From this, logistic regression analysis was used
to derive a model for the risk of development of such
complications, which was subsequently tested in a further
validation set of patients. The resulting risk index consists of
seven weighted clinical factors (Table 1). The value of this scoring
system in the prediction of the development of serious complica-
tions has subsequently been validated in both the single-centre
(Uys et al, 2004) and multicentre settings (Paesmans et al, 2003).
The aim of defining low-risk neutropenia in this way has been
to identify episodes of FN, which may be amenable to newer
approaches to treatment involving less intensive, more convenient
treatment, which may in turn be expected to have an impact
on patients’ quality of life. Such treatment strategies may also have
a potentially significant impact on health service resource
utilisation.
Most research effort has focussed on the role of oral antibiotics.
Two large multinational prospective randomised controlled trials
(Freifeld et al, 1999; Kern et al, 1999) have demonstrated
equivalence in terms of both efficacy and safety for oral antibiotics
compared to standard parenteral regimens for patients with low-
risk FN when delivered in the in-patient setting. These findings
have led to the inclusion of combination oral antibiotics as a
standard option for treatment of low-risk FN in the most recent
Infectious Diseases Society of America guidelines for the use of
antimicrobial agents in neutropenic patients with cancer (Hughes
et al, 2002). The case for oral antibiotics has been further
strengthened by a recent meta-analysis (Vidal et al, 2004) of 15
trials comparing oral and i.v. treatment, which found no difference
in failure rates or mortality between the two interventions.
The feasibility of combining an oral antibiotic regimen with
early hospital discharge has been reported in a UK population in a
randomised single-centre trial (Innes et al, 2003) which compared
this approach to standard in-patient i.v. treatment. In this study,
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snot only were the success rates of the i.v. and oral arms
comparable, but importantly the policy of oral antibiotics with
early discharge reduced median in-patient stay to only 2 days. In
turn this was associated with substantial savings both in financial
terms and in the amount of nursing care required. Although a
long-term aim, there is presently little randomised data to support
the management of low-risk FN in the outpatient setting.
The evolving management of low-risk FN on an international
level led us to investigate the current treatment policy of low-risk
FN in oncology departments across the UK. In particular, we were
interested to determine:
(i) Whether UK clinicians are assessing the likelihood of patients
developing complications related to FN and if so, whether
they are using the MASCC index or other means.
(ii) Whether UK clinicians are using oral antibiotics as first-line
treatment in any patients with FN.
(iii) What criteria UK clinicians are using to determine patients’
suitability for hospital discharge and whether they have
policies for early hospital discharge.
METHODS
A database of clinicians registered to a UK national trial of
prophylactic antibiotics (Cullen et al, 2005) was used to identify
249 consultant oncologists and haematologists from 60 centres
across the UK with an interest in the antibiotic management
of FN. Questionnaires were sent to these identified clinicians in
September 2003 with a covering letter explaining its aims and
rationale, a stamped addressed envelope and additional ques-
tionnaires to distribute to other relevant colleagues.
The questionnaire
The questionnaire was designed to be succinct (eight questions
covering one sheet of paper) and easy to answer consisting of
mainly tick-box responses. The name and hospital of the clinician
was preprinted onto the questionnaire. Clinicians were initially
asked whether they manage patients with FN. If not they were
asked to return the survey uncompleted, but otherwise to proceed
to answer the remaining questions. The questions related to the
three key areas specified below and clinicians were invited to also
give further comments.
Stratification and treatment of low-risk FN Clinicians were
asked whether they routinely stratify patients with FN and, if so,
to explain the criteria by which they defined ‘low-risk’. They were
then asked about their standard first-line antibiotic treatment for
non-penicillin-allergic low-risk patients with FN. They were asked
to specify whether they use an i.v. antibiotic regimen until
resolution, an i.v. regimen initially followed by ‘step-down’ oral
antibiotics or oral antibiotics from the outset and for the details of
the regimen used. There was also an additional question asking
about the timing of antibiotic discontinuation.
Criteria for hospital discharge Clinicians were asked for the
criteria they use for hospital discharge for patients recovering from
febrile netropenia. They were asked whether they take into account
temperature, neutrophil count, a combination of both or other
criteria. If temperature was used as a criterion for discharge
clinicians were asked to further define the absolute value
and duration of the patient’s defervescence, which would be
deemed appropriate for discharge. Similarly, clinicians who
specified neutrophil count as a criterion were asked for the
absolute neutrophil count which would be deemed appropriate
for discharge or alternatively whether they used a rising neutrophil
count, irrespective of the absolute value as their preferred
criterion.
Trial participation Finally, clinicians were asked whether they
would be willing to participate in a trial for low-risk FN using oral
antibiotics in conjunction with early hospital discharge.
Statistical analysis
The responses of clinicians to the questionnaire are reported
descriptively. Type of antibiotic treatment and criteria for hospital
discharge are compared between those who do or do not stratify
patients by risk using continuity-adjusted w
2 tests.
RESULTS
Of the 249 questionnaires sent out to clinicians from 60 cancer
departments across the UK, replies were received from 114 (47.4%)
clinicians who manage patients with FN. A further 14 replies were
received from clinicians who were not included in the original
mailshot but who had been passed copies of the questionnaire
by other recipients. Thus a total of 128 responding clinicians
(94 clinical/medical oncologists; 32 haematologists and two others)
who manage FN responded. These represent 50 departments
across the UK with a median of two clinicians from each centre
(range 1–7).
Stratification of FN
Of these 128 clinicians, 79 (62%) do not stratify patients with FN
into low- and high-risk categories (Figure 1). Of the 49 (38%)
who do stratify, three indicated that this was on an occasional or
informal basis. Of the 50 oncology/haematology departments
represented, 28 (56%) had at least one clinician who stratifies
patients by risk and 22 (44%) had no responding clinician who
stratifies such episodes by risk. Within the centres represented
there was a lack of consistency regarding risk stratification;
of the 29 centres from which two or more clinicians responded,
there were only five centres from which all responding clinicians
stratify by risk.
Of the 49 clinicians who stratify by risk, 43 gave the criteria by
which they define ‘low-risk’, three stated that there were no formal
criteria and three gave no further information. The criteria varied
substantially, with the majority using a combination of factors
including patients’ symptoms and signs, absolute neutrophil count
and expected duration of neutropenia, nature of the underlying
malignancy, previous episodes of neutropenia and age (Table 2).
However, very few clinicians appeared to be systematically using
a single published definition of low-risk but rather to be using
factors derived from more than one study. In addition, some
clinicians gave more general and subjective definitions, for
Table 1 MASCC Risk index
Characteristic Score
Burden of illness
No or mild symptoms
a 5
Moderate symptoms
a 3
No hypotension 5
No chronic obstructive pulmonary disease 4
Solid tumour/lymphoma or no previous fungal infection 4
No dehydration 3
Outpatient status at onset of fever 3
Age o60 years 2
aPoints attributable to burden of illness are not cumulative. The maximum
theoretical score is therefore 26. The authors used a threshold of X21 points to
define ‘low-risk’.
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sexample, ‘no sepsis’, ‘well’ etc. Responding clinicians from only
one centre (the author’s) were routinely incorporating the MASCC
risk-index into clinical practice. Clinicians who were using oral
antibiotics for low-risk patients also gave patients’ ability to
tolerate oral medication, for example, not vomiting, able to tolerate
oral medication, no severe mucositis as additional criteria for
suitability for such treatment. In addition, clinicians who had a
policy of early discharge also included additional criteria for
their suitability for example, having a carer at home, proximity
to hospital, availability of transport, together with subjective
assessment of patients, for example, ‘compliant patient’, ‘sensible
patient’.
Antibiotic regimens
Overall 43 (34%) clinicians use an i.v. antibiotic regimen until
resolution as their standard first-line treatment for non-penicillin
allergic patients with ‘low-risk’ FN, 56 (44%) use i.v. antibiotics
followed by oral antibiotics (a ‘step-down’ regimen) and 28 (22%)
use an oral antibiotic regimen from the outset in at least some of
their patients (Figure 1). Of the 49 clinicians who stratify patients,
25 (51%) use oral regimens from the outset, in marked contrast to
the 79 clinicians not stratifying by risk of whom only three (4%)
used oral regimens (Po0.0001). The range of different antibiotics
regimens utilised is shown in Table 3.
Criteria for hospital discharge
The criteria used by respondents for hospital discharge are shown
in Table 4. The majority (n¼91; 71%) used a combination of
temperature and neutrophil count as criteria for hospital discharge
(including four who stated that just one criteria is used in certain
situations and one whose criteria also included five days i.v.
antibiotics). Of the remaining respondents, 33 (26%) used only the
patient’s temperature, two (2%) used only the neutrophil count,
one specified that discharge was at the clinician’s discretion and
one did not specify. Those who stratify patients according to risk
were more likely to utilise fever lysis alone, irrespective of
neutrophil count: 17 of the 49 (35%) clinicians who do stratify
by risk use temperature only compared with 16 of the 79 (20%)
nonstratifying clinicians although this did not reach statistical
significance (P¼0.11). Of the 123 clinicians who specified
temperature criteria for discharge, almost half (n¼60; 49%)
specified p371C and half (n¼60; 49%) specified p37.51C, with
24h the most popular duration (n¼87; 71%). Of the 93 clinicians
who gave patient’s neutrophil count as part of their criteria for
discharge approximately a third (n¼32; 34%) use a rising
neutrophil count irrespective of the absolute value, while the
remainder (n¼61; 66%) have a fixed absolute neutrophil count
which they regard as being suitable for discharge.
Duration of antibiotic treatment
The majority of clinicians (n¼79; 62%) stated that in low-risk
patients antibiotics were discontinued after a minimum number
days following lysis of fever with 1–2 days specified by 14
clinicians, 2–5 days by 54 and 5–7 days by 11. A further 27 (21%)
discontinue antibiotics at (or 24h before; n¼1) discharge.
Nine clinicians (7%) discontinue after a fixed duration from onset
of fever with number of days ranging from 5 to 10. The criteria
for the remaining clinicians related to neutrophil recovery (n¼4)
or white blood count (n¼1) and eight not specifying.
Clinicians’ comments and trial participation
When asked for their further comments, clinicians from three
centres commented that they manage some patients with low-risk
FN as outpatients and a further five that they have early discharge
policies in place. A number of clinicians also made comments
regarding practical difficulties in the assessment and management
of low-risk FN. In particular, several respondents cited difficulties
with the ability of junior staff to assess risk, for example ‘junior
staff play it safe’; ‘(difficulty in determining whether) the nadir is
passed or coming’. One clinician commented that ‘in practice very
Responding clinicians
n=128 
Stratify FN by low-vs high-risk of
developing complications
n=49
Do not stratify FN by risk of
developing complications
n=79a
I.V.b
n=6
 I.V.b
n=37
Step-downc
n=18
 Oral
n=25
Step-downc
n=38
Oral
n=3
aOne respondent did not specify which antibiotic regimen was used.
bI.V. regimen until resolution.
cI.V. antibiotics followed by change to oral regimen after unspecified period.
Figure 1 Summary of clinicians’ antibiotic treatment of low-risk FN.
Table 2 Criteria used to define ‘low-risk’
Factor used to stratify risk of FN
No of clinicians
using this factor
Clinical findings 26
Absolute neutrophil count 17
Anticipated duration of neutropenia 16
Patients’ symptoms or performance status 12
Underlying malignancy (nonhaematological
or nonacute leukaemia)
9
Site of infection 8
Comorbidities 7
Age 5
Chemotherapy regimen 4
Previous fungal infection in haematological malignancy 3
Outpatient at presentation 2
Previous episodes of febrile neutropenia 1
‘Controlled’ cancer 1
Table 3 Antibiotic regimens used
Antibiotic regimen used No. (% of known) clinicians using
Oral antibiotic regimens (n¼28)
Ciprofloxacin+co-amoxiclav 18 (69)
Ciprofloxacin 8 (31)
Not specified 2
‘Step-down’ antibiotic regimens (intravenous-oral; n¼56)
Dual therapy-oral antibiotics 40 (82)
Monotherapy-oral antibiotics 9 (18)
Not specified 7
Intravenous antibiotic regimens (n¼43)
Dual therapy 25 (68)
Monotherapy 12 (32)
Not specified 6
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srarely do patients get into low-risk category’. However, respon-
dents were generally very favourable about the concept of early
discharge for patients with low-risk FN, one clinician commenting
that ‘we have real pressure on beds, anything reducing in-patient
stay would be of interest’. Of the 128 respondents, 108 (84%) said
that they would be willing to participate in a trial for low-risk FN of
oral antibiotics combined with early hospital discharge.
DISCUSSION
This study is the first to survey the UK management of FN, an
important complication of anticancer chemotherapy. Clinicians
from 50 of the 60 cancer departments surveyed (83%) responded,
giving broad representation of current treatment across the
UK. The findings suggest substantial variation in the management
of FN and a slow and/or cautious introduction of recent evidence
in this area.
Fewer than half of the responding clinicians stratify patients
with FN according to their likelihood of developing complications.
Moreover, of those who do stratify, the definition of ‘low-risk’
varies greatly, with clinicians using different combinations of a
variety of published and unpublished, objective and subjective
criteria. Clinicians from only one centre (the author’s) were using
the well-validated MASCC scoring system. Moreover, only a
quarter (22%) of respondents use oral antibiotics from the outset
in the management of any of their patients with FN. This is despite
the increasing evidence base, which demonstrates equivalence in
terms of success rates and safety for oral vs i.v. regimens in low-
risk FN (Freifeld et al, 1999; Kern et al, 1999; Innes et al, 2003), the
anticipated benefits of quality of life to patients and the potential
significant savings in utilisation of resources. Furthermore, the
study findings represent the practice of clinical trialists in the UK
in the field of FN. It may be expected that as such they are more
likely to have incorporated recent study findings into their
clinical practice. Therefore, this study may overestimate the
use of oral antibiotics in the routine management of FN in the
UK. The reasons for not implementing such policies have not been
explored in the current survey, but it is possible that some
clinicians feel that the level of staffing available is inadequate to
safely implement the close monitoring required for such policies.
Interestingly, clinicians and centres that do stratify and thus
identify low-risk patients were more likely to have introduced oral
antibiotics into their management of FN than those who do not
stratify. Thus acknowledgement of the concept of ‘low-risk’ is
accompanied by recognition that a ‘one size fits all’ management
strategy is not necessarily the most appropriate treatment of FN.
Similarly, clinicians who stratified by risk were more likely to use
only patients’ temperature rather than temperature together with
neutrophil count as criteria for determining discharge from
hospital than those who do not stratify by risk. In turn this is
likely to reflect shorter durations of hospital admission for
stratifying clinicians/centres, although this has not been formally
examined.
The published evidence presents a strong case that the
introduction of less intensive management strategies could offer
significant benefits to patients with low-risk FN in terms of
reduced hospitalisation and potentially improved quality of life. In
a previous UK study, it was estimated that the approximate costs
per episode of low-risk FN treated with oral antibiotics/early
discharge were 55% of those for a patient treated as an in-patient
treated with i.v. antibiotics (Innes et al, 2003). Approximately 70%
of all FN episodes are low-risk (Klastersky et al, 2000). Thus, if
such a management strategy could be safely achieved across the
UK, the potential resource savings would be considerable.
There is more than one strategy for using the limited available
repertoire of orally bioavailable antibacterials to combat neutro-
penic infection. Instead of using fluoroquinolones to treat
neutropenic infections for patients predicted to be at low risk of
complications, they might be used at an earlier time point as
prophylaxis. Recent results from a randomised, double-blind,
placebo-controlled trial of 1565 patients with solid tumours or
lymphoma (Cullen et al, 2005) have shown reduction in the
frequency of febrile episodes during chemotherapy in patients
receiving levofloxacin prophylaxis compared with those receiving
placebo (11 vs 16%; P¼0.01). These important results are not in
themselves sufficient to recommend a universal prophylaxis
strategy because the impact on bacterial resistance patterns has
not yet been determined. A targeted treatment approach for actual
infections using oral fluoroquinolones might enable less intensive
treatment and early hospital discharge and these potential benefits
need to be assessed. It is not known whether patients who develop
FN despite receiving prophylactic antibiotics could be still be
defined as ‘low-risk’ even if they otherwise fulfil the MASCC
criteria, since such patients have been excluded from previous
studies. Further research in this area is required.
In conclusion, the present study identifies both variations in
practice and a degree of caution in implementing evidence-based
advances in the management of FN in the UK. Better local and
national policies and guidelines are clearly needed. We believe that
Table 4 Criteria used for patient discharge. (a) Temperature and duration for those who use temperature criterion and (b) Neutrophil count criteria for
those who use it
1 reading 2 readings 4h apart 3 readings 4h apart 24h Other
a Total
(a)
p371C 0 8 1 44 7 60
p37.51C 2 10 3 41 4 60
p37.91C0 1 0 2 0 3
Total 2 19 4 87 11 123
b
(b)
Neutrophil
count only
Temperature and
neutrophil count
Other Total
X0.5 10
9/l 0 36 (and rising in 1) 0 36 (39%)
X1 10
9/l 1 18 (and rising in 3) 3 22 (24%)
Rising neurophil count irrespective of value 1 29 2 32 (34%)
Other
c 0 3 0 3 (3%)
Total 2 86 5
d 93
aIncludes 72h, 1 reading or 24, 24–48, 48, 72, 424h.
bOne respondent who stated temperature and neutrophil count as criteria for patient discharge did not actually specify the
criteria.
cIncludes 0.8 10
9/l, X0.3 10
9/l, X0.2 10
9/l and rising.
dTwo of the clinicians who specified ‘other’ criteria did not use neutrophil count.
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sthe introduction of newer strategies may be best achieved in the
setting of a well-conducted, multicentre trial. The advent of
National Cancer Research Networks across the UK provides a
unique opportunity for such a study. A randomised phase III trial
comparing standard in-patient management with early hospital
discharge in cancer patients receiving oral antibiotics for low-risk
FN has been sponsored by Cancer Research UK and will be
launched later in the year.
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